5.33
price up icon0.95%   0.05
after-market アフターアワーズ: 5.36 0.03 +0.56%
loading
前日終値:
$5.28
開ける:
$5.31
24時間の取引高:
694.70K
Relative Volume:
0.46
時価総額:
$237.22M
収益:
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.2968
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-6.98%
1か月 パフォーマンス:
+15.87%
6か月 パフォーマンス:
+55.85%
1年 パフォーマンス:
-52.03%
1日の値動き範囲:
Value
$5.12
$5.42
1週間の範囲:
Value
$5.01
$6.02
52週間の値動き範囲:
Value
$2.10
$14.22

Verastem Inc Stock (VSTM) Company Profile

Name
名前
Verastem Inc
Name
セクター
Healthcare (1174)
Name
電話
(781) 292-4200
Name
住所
117 KENDRICK STREET, NEEDHAM, MA
Name
職員
73
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
VSTM's Discussions on Twitter

VSTM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VSTM
Verastem Inc
5.33 237.22M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.00 108.68B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.58 74.90B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
640.52 38.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.27 31.76B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.93 26.83B 3.30B -501.07M 1.03B -2.1146

Verastem Inc Stock (VSTM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-31 繰り返されました BTIG Research Buy
2024-09-30 開始されました Guggenheim Buy
2023-11-21 再開されました BTIG Research Buy
2023-09-27 開始されました B. Riley Securities Buy
2023-06-15 アップグレード Mizuho Neutral → Buy
2022-09-07 再開されました Alliance Global Partners Buy
2022-04-29 再開されました Cantor Fitzgerald Overweight
2022-04-14 開始されました RBC Capital Mkts Outperform
2022-03-09 開始されました Truist Buy
2021-07-01 開始されました Alliance Global Partners Buy
2021-05-24 アップグレード BTIG Research Neutral → Buy
2019-06-20 ダウングレード BTIG Research Buy → Neutral
2019-05-10 ダウングレード Raymond James Outperform → Mkt Perform
2018-07-13 開始されました BTIG Research Buy
2018-05-02 開始されました Seaport Global Securities Buy
2018-03-08 開始されました B. Riley FBR, Inc. Buy
2017-09-07 繰り返されました H.C. Wainwright Buy
2017-04-13 開始されました Oppenheimer Outperform
2017-03-24 繰り返されました H.C. Wainwright Buy
2015-09-29 ダウングレード Cantor Fitzgerald Buy → Hold
2015-09-29 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 ダウングレード Jefferies Buy → Hold
2015-09-29 ダウングレード Raymond James Strong Buy → Outperform
2015-09-28 ダウングレード Mizuho Buy → Neutral
2015-09-28 ダウングレード ROTH Capital Buy → Neutral
2015-09-09 開始されました Raymond James Strong Buy
2015-05-12 繰り返されました UBS Buy
2015-04-08 開始されました H.C. Wainwright Buy
2015-01-23 繰り返されました ROTH Capital Buy
2014-07-08 再開されました Oppenheimer Perform
2014-02-11 開始されました Mizuho Buy
すべてを表示

Verastem Inc (VSTM) 最新ニュース

pulisher
Jan 17, 2025

Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL

Jan 17, 2025
pulisher
Jan 16, 2025

Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada

Jan 16, 2025
pulisher
Jan 16, 2025

Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace

Jan 15, 2025
pulisher
Jan 15, 2025

Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan

Jan 15, 2025
pulisher
Jan 15, 2025

Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com

Jan 15, 2025
pulisher
Jan 14, 2025

Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem CEO sells shares worth $44,896 - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire

Jan 14, 2025
pulisher
Jan 14, 2025

Verastem Oncology announces debt refinancing with Oberland Capital - MSN

Jan 14, 2025
pulisher
Jan 13, 2025

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace

Jan 13, 2025
pulisher
Jan 09, 2025

Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News

Jan 08, 2025
pulisher
Jan 08, 2025

Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail

Jan 08, 2025
pulisher
Jan 08, 2025

Follicular Lymphoma Market Expected to rise, 2034 | - openPR

Jan 08, 2025
pulisher
Jan 08, 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

Verastem Oncology Grants Stock Options to New Employee at $6.49 Exercise Price - StockTitan

Jan 08, 2025
pulisher
Jan 07, 2025

Chugai Pharmaceutical Co., Ltd.Verastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com

Jan 07, 2025
pulisher
Jan 07, 2025

Royal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - MarketBeat

Jan 07, 2025
pulisher
Jan 05, 2025

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN

Jan 05, 2025
pulisher
Jan 04, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Analysts - Defense World

Jan 04, 2025
pulisher
Jan 04, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Jan 04, 2025
pulisher
Jan 03, 2025

Verastem: Planning The PDUFA Run-Up (NASDAQ:VSTM) - Seeking Alpha

Jan 03, 2025
pulisher
Jan 03, 2025

State Street Corp Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

Verastem: BLA Acceptance Puts Key Goals In Sight (NASDAQ:VSTM) - Seeking Alpha

Jan 02, 2025
pulisher
Jan 02, 2025

Verastem soars on FDA priority review for avutometinib - The Pharma Letter

Jan 02, 2025
pulisher
Jan 01, 2025

Verastem stock climbs on raised price target and FDA milestone for KRASm treatment - Investing.com Nigeria

Jan 01, 2025
pulisher
Jan 01, 2025

Verastem stock remains volatile but promising data reinforces Buy rating by B.Riley - Investing.com Canada

Jan 01, 2025
pulisher
Jan 01, 2025

BTIG Research Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Thera - GuruFocus.com

Dec 31, 2024
pulisher
Dec 31, 2024

Verastem Shares Soar on FDA Priority Review of Cancer Treatment - Marketscreener.com

Dec 31, 2024
pulisher
Dec 31, 2024

FDA sets priority review date for Verastem’s new ovarian cancer drug - The Business Journals

Dec 31, 2024
pulisher
Dec 31, 2024

Regulatory Milestone Sends Verastem (VSTM) Shares Soaring - Stocks Telegraph

Dec 31, 2024
pulisher
Dec 31, 2024

Stifel Financial Corp Buys 11,642 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application - Yahoo Finance

Dec 31, 2024
pulisher
Dec 31, 2024

Verastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG Research - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - BioSpace

Dec 31, 2024
pulisher
Dec 30, 2024

Verastem Oncology's New Cancer Treatment Gets FDA Priority Review - Marketscreener.com

Dec 30, 2024
pulisher
Dec 30, 2024

FDA accepts Verastem NDA for priority review, stock jumps 20% (update) - Seeking Alpha

Dec 30, 2024

Verastem Inc (VSTM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):